Using a CGM on a GLP-1
Put a continuous glucose monitor on someone starting semaglutide or tirzepatide and, within a week or two, the trace changes shape. The post-meal peaks flatten. The overnight line steadies. It is one of the more satisfying things to watch in metabolic medicine, and it is also — for most people — not a reason to wear the monitor.
This page is about when a CGM earns its place alongside a GLP-1, when it is a two-week curiosity, and the one situation in which it is a safety tool rather than a feedback tool.
What the trace shows on a GLP-1
GLP-1 medications slow gastric emptying, increase insulin release in response to food, and suppress the glucagon that pushes glucose out of the liver. On a monitor, that reads as smaller and slower rises after eating, lower variability across the day, and — in someone who started with a prediabetic pattern — a trace that begins to look normal.
That last observation is the useful one. For a person with prediabetes, the CGM hub page explains that the monitor's value is as biofeedback inside a structured plan, not as a standalone tool. A GLP-1 is that plan's most powerful component, and the monitor shows its effect on the thing the person was worried about — glucose — rather than only on the scale. The tirzepatide prediabetes page covers the three-year evidence; the CGM is how a patient sees the first three weeks of it.
For a person with normal glucose who is on a GLP-1 purely for weight, the trace was flat before and is flatter now. There is little to learn, and the risk the hub page describes — reading normal fluctuation as a problem, restricting unnecessarily — applies with full force.
When it is worth adding
Prediabetes at baseline. The strongest case. The monitor shows whether the pattern is normalizing, which is the actual goal, and it shows it long before an A1c can — see CGM vs A1c.
A plateau, or a stall. When weight stops moving, a two-week trace sometimes reveals why: an evening pattern, a food that the person did not think of as sugar, a sleep problem visible as overnight variability. It is a diagnostic run, not a permanent accessory.
The person who wants to keep the result after stopping. For someone planning to come off a GLP-1 eventually — which the trial data say is when the metabolic gains begin to reverse — a monitor in the last weeks on the drug and the first weeks off it shows what the drug had been doing and what now has to be done by other means. That is a legitimate and under-used application.
When it is noise
A person with normal glucose, no metabolic history, on a GLP-1 for weight, who is losing weight as expected, gains nothing from a CGM that a scale and a quarterly panel do not provide. The number-watching can become its own problem. We will say so rather than sell it.
The membership page FAQ mentions that a CGM can be added; this page is the reason we sometimes say it should not be.
The one safety case
GLP-1 medications on their own very rarely cause low blood sugar. Combined with a medication that pushes insulin out regardless of glucose — a sulfonylurea, or insulin itself, in a person with type 2 diabetes — they can. The label for every GLP-1 warns about it, and the risk is highest in the first weeks and with reduced eating.
For that person, a CGM is not biofeedback. It is an alarm. It shows a downward drift before it becomes a symptom, and it is the reason we would ask the clinician who manages the diabetes to consider one when a GLP-1 is added. Diabetes management is not ours; flagging the interaction is. The after-60 page covers why the medication list matters more with age.
What we do not do with the data
We do not set glucose targets on a GLP-1 that are stricter than the standard ranges, and we do not adjust the GLP-1 on the basis of a CGM trace — the medication is prescribed for weight and metabolic health on the schedule the clinician sets, and the monitor observes rather than directs. A trace is a conversation at the next review, not a reason to change anything between reviews.
Frequently asked questions
Most people do not. It is worth adding for someone with prediabetes at baseline, for a diagnostic run during a stall, or around stopping the medication. For normal glucose and steady weight loss it adds little.
Smaller, slower rises after meals, less variability, and — in someone who started with a prediabetic pattern — a trace that normalizes within weeks.
Rarely on its own. Combined with a sulfonylurea or insulin in someone with diabetes, yes, and in that case a CGM is a safety tool managed with the diabetes clinician.
Not directly. It can explain a plateau or show a pattern worth changing. It does not add to the drug's effect.
It is one of the better uses: a monitor across the transition shows what the drug had been doing and what lifestyle now has to cover.
No. The trace is discussed at review; the medication is not changed on the basis of it between reviews.
Where this fits in your plan
The Continuous Glucose Monitor page covers the evidence and who the monitor helps. The membership is where it is added, when it should be.
We measure first. Then we act.
References
- Wegovy (semaglutide) and Zepbound (tirzepatide) prescribing information — Section 5, Warnings: hypoglycemia with concomitant insulin secretagogues or insulin.
- Klonoff DC et al. Continuous glucose monitoring in people without diabetes: a narrative review. JAMA Internal Medicine 2026; doi 10.1001/jamainternmed.2026.2772.
- European Journal of Medical Research, January 2026 — systematic review and meta-analysis of CGM in non-diabetic adults (23 studies).
- American Diabetes Association. Standards of Care in Diabetes — 2026, Section 7: Diabetes Technology.
- Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. NEJM 2024 — off-treatment period.
- Back toContinuous Glucose Monitor
- CGM vs A1c vs fasting glucoseThey are not three versions of one number. A1c averages three months, fasting glucose catches one moment, a CGM watches two weeks. Where they disagree and which you need.Read
- Tirzepatide for prediabetesOver three years, tirzepatide cut progression from prediabetes to type 2 diabetes by 94%. What SURMOUNT-1 showed, what happened when it stopped, and who this is for.Read
- Weight Loss Program MembershipMonthly clinical oversight and plan adjustment for members using branded GLP-1 medications.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.